Want to see JP:4575 full AI Analyst Report?

CanBas Co., Ltd. (4575) Price & Analysis

0 Followers

4575 Stock Chart & Stats

¥787.00

-¥23.00(-2.48%)

At close: Jan 08 4:00 PM EST

¥787.00

-¥23.00(-2.48%)

Day’s Range― - ―

52-Week Range¥506.00 - ¥991.00

Previous CloseN/A

Volume347.00K

Average Volume (3M)117.56K

Market Cap

¥14.81B

Enterprise Value¥10.24B

Total Cash (Recent Filing)¥1.45B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.83

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-66.43

Shares Outstanding19,770,655

10 Day Avg. Volume126,950

30 Day Avg. Volume117,563

Financial Highlights & Ratios

PEG Ratio-1.02

Price to Book (P/B)7.12

Price to Sales (P/S)0.00

P/FCF Ratio-8.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetThe absence of reported debt reduces solvency and interest-burden risk while giving CanBas more financial flexibility than during FY2021–FY2022, when leverage was materially higher. This provides a durable balance-sheet advantage as the company continues funding its development activities.

Oncology Development FocusA concentrated oncology focus can support deeper expertise and a clearer development strategy than a broadly diversified early-stage portfolio. Continued preclinical and clinical activity gives CanBas a defined route toward potential product commercialization, although success remains dependent on development outcomes.

External Commercialization PathwaysExternal collaboration provides CanBas with a route to advance candidates beyond internal research and pursue commercialization without relying exclusively on its small organization. Partnerships can broaden development capabilities and market access if the pipeline achieves sufficient clinical and commercial progress.

Bears Say

No Recent RevenueThe absence of revenue since FY2022 indicates that CanBas has not yet established a recurring commercial business base. Without product sales, the company remains dependent on development progress and external funding, making financial performance highly sensitive to the timing and success of future commercialization.

Persistent LossesLarge recurring net losses show that the current operating model is not profitable and that research and development spending has not yet translated into sustainable earnings. Continued losses can constrain strategic flexibility and require CanBas to secure additional capital before products generate meaningful revenue.

Ongoing Cash Burn And Equity ErosionPersistent negative operating and free cash flow means the business is not self-funding, while falling equity reflects the cumulative cost of ongoing losses. Continued cash consumption increases reliance on external financing and raises the potential for future dilution if additional funding is required.

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?

CanBas Co., Ltd. lowest stock price was ¥506.00 and its highest was ¥991.00 in the past 12 months.

What is CanBas Co., Ltd.’s market cap?

CanBas Co., Ltd.’s market cap is ¥14.81B.

When is CanBas Co., Ltd.’s upcoming earnings report date?

CanBas Co., Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 13 days.

How were CanBas Co., Ltd.’s earnings last quarter?

CanBas Co., Ltd. released its earnings results on Aug 12, 2026. The company reported -¥22.07 earnings per share for the quarter.

Is CanBas Co., Ltd. overvalued?

According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CanBas Co., Ltd. pay dividends?

CanBas Co., Ltd. does not currently pay dividends.

What is CanBas Co., Ltd.’s EPS estimate?

CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CanBas Co., Ltd. have?

CanBas Co., Ltd. has 19,770,655 shares outstanding.

What happened to CanBas Co., Ltd.’s price movement after its last earnings report?

CanBas Co., Ltd. reported an EPS of -¥22.07 in its last earnings report. Following the earnings report the stock price went down -1.195%.

Which hedge fund is a major shareholder of CanBas Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4575

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CanBas Co., Ltd.

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.